Targeted  	Targeted  	 JJ	B-NP
therapy  	therapy  	 NN	I-NP
for  	for  	 IN	I-NP
hereditary  	hereditary  	 JJ	I-NP
cancer  	cancer  	 NN	I-NP
syndromes 	syndromes 	 NNS	I-NP
:  	:  	 :	O
neurofibromatosis  	neurofibromatosis  	 JJ	B-NP
type  	type  	 NN	I-NP
1 	1 	 CD	O
,  	,  	 ,	O
neurofibromatosis  	neurofibromatosis  	 JJ	B-NP
type  	type  	 NN	I-NP
2 	2 	 CD	O
,  	,  	 ,	O
and  	and  	 CC	O
Gorlin  	Gorlin  	 NNP	B-NP
syndrome  	syndrome  	 NN	I-NP
Hereditary  	Hereditary  	 NNP	I-NP
cancer  	cancer  	 NN	I-NP
syndromes  	syndromes  	 NNS	I-NP
are  	are  	 VBP	O
well  	well  	 RB	O
known  	known  	 VBN	O
in  	in  	 IN	O
the  	the  	 DT	O
oncology  	oncology  	 JJ	B-NP
community 	community 	 NN	I-NP
,  	,  	 ,	O
typically  	typically  	 RB	O
affecting  	affecting  	 VBG	B-NP
children 	children 	 NNS	I-NP
,  	,  	 ,	O
adolescents 	adolescents 	 NNS	O
,  	,  	 ,	O
and  	and  	 CC	O
young  	young  	 JJ	O
adults  	adults  	 NNS	O
and  	and  	 CC	O
thereby  	thereby  	 RB	O
resulting  	resulting  	 VBG	O
in  	in  	 IN	O
great  	great  	 JJ	O
cumulative  	cumulative  	 JJ	B-NP
morbidity  	morbidity  	 NN	I-NP
and  	and  	 CC	O
mortality 	mortality 	 NN	O
.  	.  	 .	O
These  	These  	 DT	O
syndromes  	syndromes  	 NN	O
often  	often  	 RB	O
lag  	lag  	 VB	O
behind  	behind  	 IN	O
their  	their  	 PRP$	O
de  	de  	 FW	B-NP
novo  	novo  	 FW	I-NP
counterparts  	counterparts  	 NNS	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
development  	development  	 NN	O
of  	of  	 IN	O
approved  	approved  	 JJ	O
novel  	novel  	 NN	O
treatment  	treatment  	 NN	O
options  	options  	 NNS	O
due  	due  	 JJ	O
to  	to  	 TO	O
their  	their  	 PRP$	O
rarity  	rarity  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
general  	general  	 JJ	O
population 	population 	 NN	O
.  	.  	 .	O
Recent  	Recent  	 JJ	B-NP
work  	work  	 NN	I-NP
has  	has  	 VBZ	O
allowed  	allowed  	 VBN	O
the  	the  	 DT	O
identification  	identification  	 NN	B-NP
of  	of  	 IN	I-NP
molecular  	molecular  	 JJ	I-NP
aberrations  	aberrations  	 NN	I-NP
and  	and  	 CC	O
associated  	associated  	 VBN	O
targeted  	targeted  	 VBN	B-NP
therapies  	therapies  	 NNS	I-NP
that  	that  	 WDT	O
may  	may  	 MD	O
effectively  	effectively  	 RB	O
treat  	treat  	 VB	O
these  	these  	 DT	O
conditions 	conditions 	 NNS	O
.  	.  	 .	O
In  	In  	 IN	O
this  	this  	 DT	O
review 	review 	 NN	O
,  	,  	 ,	O
we  	we  	 PRP	O
seek  	seek  	 VBP	O
to  	to  	 TO	O
characterize  	characterize  	 VB	O
some  	some  	 DT	O
of  	of  	 IN	O
the  	the  	 DT	O
involved  	involved  	 JJ	O
aberrations  	aberrations  	 NN	O
and  	and  	 CC	O
associated  	associated  	 VBN	O
targeted  	targeted  	 VBN	B-NP
therapies  	therapies  	 NNS	I-NP
for  	for  	 IN	O
several  	several  	 JJ	O
germline  	germline  	 JJ	B-NP
malignancies 	malignancies 	 NN	I-NP
,  	,  	 ,	O
including  	including  	 VBG	O
neurofibromatosis  	neurofibromatosis  	 JJ	B-NP
types  	types  	 NNS	I-NP
1  	1  	 CD	O
and  	and  	 CC	O
2 	2 	 CD	O
,  	,  	 ,	O
and  	and  	 CC	O
Gorlin  	Gorlin  	 NNP	B-NP
syndrome 	syndrome 	 NN	I-NP
.  	.  	 .	O
Though  	Though  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
hereditary  	hereditary  	 JJ	B-NP
cancer  	cancer  	 NN	I-NP
syndromes  	syndromes  	 NNS	I-NP
may  	may  	 MD	O
be  	be  	 VB	O
too  	too  	 RB	O
rare  	rare  	 JJ	O
to  	to  	 TO	O
effectively  	effectively  	 RB	O
include  	include  	 VB	O
in  	in  	 IN	O
large  	large  	 JJ	O
clinical  	clinical  	 JJ	B-NP
trials 	trials 	 NNS	I-NP
,  	,  	 ,	O
by  	by  	 IN	O
understanding  	understanding  	 VBG	O
the  	the  	 DT	O
pathophysiology  	pathophysiology  	 NN	B-NP
of  	of  	 IN	O
these  	these  	 DT	O
diseases 	diseases 	 NNS	O
,  	,  	 ,	O
clinicians  	clinicians  	 NNS	B-NP
can  	can  	 MD	O
attain  	attain  	 VB	O
insights  	insights  	 NNS	O
into  	into  	 IN	O
the  	the  	 DT	O
use  	use  	 NN	O
of  	of  	 IN	O
targeted  	targeted  	 JJ	O
therapies  	therapies  	 NNS	O
in  	in  	 IN	O
their  	their  	 PRP$	O
own  	own  	 JJ	O
practice  	practice  	 NN	O
when  	when  	 WRB	O
treating  	treating  	 VBG	O
affected  	affected  	 JJ	O
individuals 	individuals 	 NNS	O
.  	.  	 .	O
